HbA1c: a review of non-glycaemic variables

Abstract

<jats:p>Identification of the correlation between HbA1c and diabetic complications has yielded one of the most clinically useful biomarkers. HbA1c has revolutionised the diagnosis and monitoring of diabetes mellitus. However, with widespread adoption of HbA1c has come increasing recognition that non-glycaemic variables can also affect HbA1c, with varying clinical significance. Furthermore, the identification of a discrepancy between predicted and measured HbA1c in some individuals, the so-called ‘glycation gap’, may be clinically significant. We aimed to review the current body of evidence relating to non-glycaemic variables to quantify any significance and provide subsequent suggestions. A PubMed-based literature search was performed, using a variety of search terms, to retrieve articles detailing the non-glycaemic variables suggested to affect HbA1c. Articles were reviewed to assess the relevance of any findings in clinical practice and where possible guidance is given. A range of non-glycaemic variables have statistically significant effects on HbA1c. While the clinical implications are generally irrelevant, a small number of non-glycaemic variables do have clinically significant effects and alternative biomarkers should be considered instead of, or in addition to, HbA1c. There are a small number of non-glycaemic variables which have a clinically significant effect on HbA1c, However, the vast majority of non-glycaemic variables have no clinical relevance. While clinicians should have an awareness of those non-glycaemic variables with clinical significance, in the vast majority of clinical scenarios HbA1c should continue to be used with confidence.</jats:p>

A Review of Continuous Glucose Monitoring-Based Composite Metrics for Glycemic Control

“…Although HbA1c can provide a rapid evaluation of glycemia over a course of 8-12 weeks, it has well described limitations. 8 Compared to HbA1c, continuous glucose monitor (CGM) can provide a better assessment of the glycemic control, without the measuring of HbA1c. CGM classifies glucose levels into various dimensions over many days that can be expressed as mean glucose levels, time spent within optimal glucose ranges, time spent above acceptable levels, time spent below acceptable levels, numbers of episodes of glucose per unit of time that are either above or below defined cut-points, glycemic variability, and rates of change.…”

Glycaemic patterns in healthy elderly individuals and in those with impaired glucose metabolism – exploring the relationship with nonglycaemic variables

“…Glucose concentrations are similar in the intra-and extracellular compartments due to the glucose T1 channel homeostatic mechanism, which is markedly expressed in the microvascular system of the kidneys. Hyperglycaemic metabolic state causes an intracellular toxic effect which leads to microvascular complications with time [12].…”

Hemoglobinopathies and Hemoglobin A1c in Diabetes Mellitus

“…9 Racial discordances between HbA1c concentrations and other measures of glycemic control are unexplained. 10 Identifying genes underlying racial differences in hemoglobin glycation would add credence that the differences are real and that genetic strategies may be useful for determining proper treatment based on the level of mean glycemia suggested by HbA1c values. 11 The hemoglobin S variant hemoglobinopathy occurs more frequently in blacks then in nHws.…”